testosterone cypionate dosage

Neutropenia, febrile neutropenia in patients receiving intensive myelosuppressive cytotoxic chemotherapy for malignancy (with the exception of chronic testosterone cypionate dosage myeloid leukemia and myelodysplastic syndrome), as well as neutropenia and its clinical consequences in patients receiving myeloablative therapy followed by allogeneic or autologous bone marrow transplantation, with an increased the risk of a prolonged and severe neutropenia.

Mobilization of autologous peripheral blood stem cells (autologous PBSC), including after myelosuppressive therapy, as well as the mobilization of peripheral blood stem cells from a healthy donor (allogeneic PBSC).

Severe congenital, intermittent or idiopathic neutropenia (absolute neutrophil count  in children and adults with severe or recurrent infections in history to increase the number of neutrophils, as well as to reduce the frequency and duration of the infection.

Persistent neutropenia in patients with advanced HIV infection to reduce the risk of bacterial infections when it is impossible to use other methods of treatment.

Neutropenia in patients with acute myeloid leukemia receiving induction chemotherapy or consolidating, to reduce its duration and clinical consequences.

Hypersensitivity to the drug or its components in history.
Severe congenital neutropenia (Kostmann’s syndrome) with cytogenetic disorders (see. “Safety Precautions” section).
Testosterone cypionate dosage should not be used to increase the dose of cytotoxic chemotherapy drugs above recommended.
Co-administration of cytotoxic chemotherapy and radiation therapy.


Standard regimens of cytotoxic chemotherapy

At 0.5 million units (5 micrograms) / kg 1 time a day every day n / a or a short in / infusion (30 minute) 5% glucose solution. In most cases, the preferred n / a route of administration. There is evidence that at / in the introduction of the drug occurs shortening of the duration of the effect. However, it remains unclear clinical significance of these data. Choosing the route of administration should depend on the individual characteristics of the patient and the clinical picture of the disease. The first dose of the drug  is administered no earlier than 24 hours after completion of cytotoxic chemotherapy. Daily administration should continue as long as the number of neutrophils exceeds the expected minimum, and will not reach normal values. After the course of chemotherapy (standard circuit) for the treatment of solid tumors, lymphomas and lymphoid leukemia therapy duration to achieve the desired effect, generally up to 14 days. Following induction and consolidation therapy of acute myeloid leukemia testosterone cypionate dosage the duration of the use of can be increased to 38 days, depending on the type, dose and use the scheme of cytotoxic chemotherapy.

A transient increase in neutrophil count is usually observed after 1-2 days after the start of treatment with Neupogen ® . To achieve a stable therapeutic effect should continue therapy with Neupogen ® as long as the number of neutrophils exceeds the expected minimum, and will not reach normal values. Do not cancel Neupogen ® prematurely, before the transfer of the number of neutrophils through the expected minimum.

Use in children – see “Features of the application of the drug in pregnant women, women during the period of breastfeeding, children and adults with chronic diseases.”.


Mobilization of peripheral blood stem cells (PBSC) in patients receiving myelosuppressive and testosterone cypionate dosage myeloablative therapy with autologous PBSC transfusion with (or without) a bone marrow transplant

To mobilize PBSC – by 1.0 million units (10 micrograms) / kg per day by s / c injection of 1 times a day, or a continuous 24-hour p / infusion (20 ml of 5% glucose solution (see section “Notes on breeding. “section” dosage and administration “)) for 5-7 days in a row, at the same time is usually enough for one or two leukapheresis procedure in a row on the 5th, 6th days. In some cases, the possibility of further leukapheresis. Appointment of the drug Neupogen ® should continue until the last leukapheresis. testobolin

arredo palestra elastici fitness dadobox